Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $19.00 Price Target at TD Cowen

Key Points

• TD Cowen raised its price target on Ultragenyx from $18 to $19 and maintained a Buy rating, implying 11.1% upside from the prior close.
• Analyst sentiment is mixed: MarketBeat reports a consensus Hold rating and $33.70 average price target, while recent firms have adjusted targets and ratings in different directions.
• Ultragenyx’s third-quarter revenue and EPS both missed estimates, though revenue grew 8.2% year over year and its per-share loss narrowed. The company reaffirmed its 2026 revenue and 2027 profitability outlook.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price increased by research analysts at TD Cowen from $18.00 to $19.00 in a report released on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. TD Cowen's price objective points to a potential upside of 11.10% from the company's previous close.

A number of other research firms also recently issued reports on RARE. The Goldman Sachs Group decreased their target price on shares of Ultragenyx Pharmaceutical from $19.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday. William Blair raised Ultragenyx Pharmaceutical to a "hold" rating in a report on Wednesday, September 23rd. Evercore downgraded Ultragenyx Pharmaceutical from an "outperform" rating to an "in-line" rating and set a $16.00 price target for the company. in a report on Thursday, September 3rd. Jefferies Financial Group lowered their price objective on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, September 3rd. Finally, Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a "neutral" rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of "Hold" and a consensus price target of $33.70.

Ultragenyx Pharmaceutical Stock Up 2.8%

Shares of Ultragenyx Pharmaceutical stock traded up $0.47 on Wednesday, reaching $17.10. 4,231,209 shares of the stock were exchanged, compared to its average volume of 2,856,926. The business has a 50 day moving average price of $16.64 and a two-hundred day moving average price of $22.81. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -2.93 and a beta of 0.37. Ultragenyx Pharmaceutical has a twelve month low of $12.73 and a twelve month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. The company's revenue for the quarter was up 8.2% on a year-over-year basis. During the same period last year, the firm posted ($1.81) EPS. Research analysts forecast that Ultragenyx Pharmaceutical will post -4.30 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,066 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the sale, the chief financial officer owned 89,229 shares of the company's stock, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 8,510 shares of company stock valued at $127,561. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $355,746,000. Bank of America Corp DE purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $38,347,000. Jefferies Financial Group Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $31,040,000. Eagle Health Investments LP purchased a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $29,521,000. Finally, Candriam S.C.A. lifted its position in Ultragenyx Pharmaceutical by 37.1% during the first quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company's stock worth $22,965,000 after buying an additional 296,798 shares during the period. Institutional investors and hedge funds own 97.67% of the company's stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It expects substantial cost reductions, including at least a 50% decrease in 2027 R&D expenses versus 2025. The company also reported FDA approvals for GENGLYCOS and FAYUVI and agreements to sell two priority review vouchers for a combined $413 million. Ultragenyx Q3 results and outlook
• Positive Sentiment: Although the quarterly loss was wider than expected, it narrowed to $1.16 per share from $1.81 a year earlier, while revenue grew 8.2% year over year. Q3 earnings report
• Neutral Sentiment: Analyst views were mixed. Morgan Stanley raised its target to $22 and Wells Fargo to $19, both retaining equal-weight ratings; Wedbush cut its target to $22 but stayed neutral. Morgan Stanley ratings Wells Fargo ratings Wedbush ratings
• Negative Sentiment: Q3 revenue of $173 million fell short of the $182.49 million consensus, and the $1.16-per-share loss was slightly worse than expected. Goldman Sachs lowered its target from $19 to $17 and kept a neutral rating. Goldman Sachs ratings
• Negative Sentiment: A Seeking Alpha analysis argued that the profitability plan relies heavily on R&D cuts, while revenue remains concentrated in CRYSVITA and pipeline setbacks have narrowed the company’s growth prospects. Ultragenyx analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.